Publications

Search our bibliography using the filters on the right-hand side.

Displaying 301 through 350 of 698 publications.

Herring W, Keenan A, Mauskopf J, Michael T, Wiegand F. The potential economic value of disease-modifying treatments in Alzheimer's disease: patient-level simulation of predementia symptom trajectories. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A12.

DeMuro C, Gnanasakthy A, Price M, Winnette R, Desphande A. Development of a daily diary to assess signs and symptoms of genital herpes. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A80.

Mansfield CA, Boeri M, Reyes C, Masaquel AS, Sutphin JN, Li J. How can we assess the impact of cost on patient treatment preferences in CLL treatment? Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A118.

Sherif B, Graham CN, Neidhardt K, Gilloteau I, O'Neill CB, Mcbride D, Augustin M. EQ-5D-3L utilities tariffs: differences in German and UK utilities and QALYS in patients with moderate to severe psoriasis. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A331.

Goeree R, Gladman D, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM. Cost-effectiveness analysis of secukinumab in psoriatic arthritis: a Canadian perspective. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A145.

Goyal RK, Ajmera MR, Davis KL. Recent trends in emergency department visits resulting from unintentional overdose of non-opioid analgesics, antipyretics, and antirheumatics in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A231.

Nagar SP, Sato M, Montgomery W, Nakamura T, Imagawa H, Davis KL. Treatment patterns and characteristics of adult patients with attention deficit/hyperactivity disorder receiving atomoxetine in Japan. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A305.

Nagar SP, Fox KM, Rane PP, Beaubrun A, Qian Y, Inomata H, Davis KL, Meyers J, Kajinami K. Incidence of cardiovascular events among secondary prevention patients treated with statins or ezetimibe in Japan. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A261.

Zuluaga S, Hess LM, Wolowacz S, Dyachkova Y, Hawe E, Vickers AD, Kaye JA, Bertwistle D. Cost-effectiveness of olaratumab in combination with doxorubicin for the treatment of locally advanced or metastatic soft tissue sarcoma in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A108.

Johnson KD, Jiang Y, Weiss T, Graham J. Herpes zoster vaccine effectiveness and waning of effectiveness. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A326.

Park J, Covert D, Fairchild C, Brubaker M, Martin SA, Lewis S, DeMuro C. Development of an eye drop comfort measure for topical ocular drop application. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A364.

Azzabi Zouraq I, Wilson M, Heather G, Curtis R, Luo M, Khalid JM, Minda K. Cost-effectiveness of vedolizumab compared with ustekinumab as treatment for patients with moderately to severely active Crohn´s disease in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A183.

Dave I, Nagar SP, Arif AA, Laditka SB, Huber LR. Association between prescription-taking status and total direct health care cost among patients with asthma. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 24, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A357.

Puig L, Griffiths CE, Zhou Y, Gilloteau I, Guana A, Houghton K, Stull DE. Differential effects of secukinumab vs. ustekinumab for treatment of moderate to severe psoriasis on work productivity and activity impairment: a structural equation modelling approach using the CLEAR 52-week study. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A161.

Fehnel SE, Ervin CM, Carson RT, Rigoni G, Lackner JM, Coons SJ. Development of the diary for irritable bowel syndrome symptoms to assess treatment benefit in clinical trials: foundational qualitative research. Value Health. 2017 Apr;20(4):618-26.

Wolowacz S. New ISPOR recommendations - mapping methods for estimation of health state utility. Value Health. 2017 Jan;20(1):28-9. doi: 10.1016/j.jval.2016.11.026

Wolowacz S. Editorial: ISPOR good research practices task force report—mapping to estimate utility values from non–preference-based outcome measures. Value Health. 2017 Jan;20(1):28-9. doi: 10.1016/j.jval.2016.11.026

Gnanasakthy A, Mordin M, Evans E, Doward L, DeMuro C. A review of patient-reported outcome labeling in the United States (2011-2015). Value Health. 2017;20(3):420-9. doi: 10.1016/j.jval.2016.10.006

Poulos C, Standaert B, Sloesen B, Hauber AB. What motivates mothers to pay for a vaccine against children's diarrhea? Preferences for vaccines against children's diarrheal illness among mothers in Poland and Hungary. Poster presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A419.

Poulos C, Curran D, Anastassopoulou A, De Moerlooze L. German travelers' preferences for vaccines against travel-related illnesses. Poster presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A419-20.

Chirila C, Mitra D, Colosia A, Ling C, Odom D, Iyer S, Kaye JA. Efficacy of palbociclib combinations versus endocrine therapies in advanced/ metastatic breast cancer: network meta-analysis. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A710.

Stull DE, Houghton K, Ainsworth C, Brown J, Bowman L, Boye ME. "Causal cascade" among outcomes in non-small cell lung cancer: assessing the direct and indirect effects of symptoms on health-related quality of life (HRQL) outcomes. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A748.

Balp M, Abuzakouk M, Berard F, Canonica GW, Gimenez-Arnau A, Hollis K, Khalil S, Knulst A, Lacour J, Lynde C, Marsland A, Maurer M, Mcbride D, Nakonechna A, Ortiz De Frutoz FJ, Oude Elberink J, Proctor C, Sussman G, Weller K, Grattan C. Comparison of direct healthcare costs associated with chronic spontaneous/idiopathic urticaria in 7 countries - results from the ASSURE-CSU study. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A565.

Le Moine J, Abeysinghe SS. Comparison of Bayesian network meta-analyses in a WinBUGS and SAS framework. Poster presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A393.

Augustin M, Krieger T, Mcbride D, Graham CN, Melzer N, Kneidl J, Neidhardt K. Cost-effectiveness of secukinumab as first biologic treatment for psoriasis compared with initiating other biologic therapy in Germany. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A568-9.

Elroy PW, Ronquest NA, Barnes A, Nadipelli VR, Akehurst R. Evaluating the effectiveness of treatments of opioid use disorder based on recovery outcomes: how to bridge the disconnect between clinical trial outcomes and recovery outcomes? Poster presented at the 2016 ISPOR 19th Annual European Congress; October 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A361.

Wheeler A, Sacco P, Rakhit A, Cabo R. Identifying the unmet medical need of Angelman Syndrome: results of a targeted literature review. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A579.

Hollis K, Abuzakouk M, Balp M, Berard F, Canonica GW, Gimenez-Arnau A, Grattan C, Khalil S, Knulst AC, Lacour J, Lynde C, Maurer M, Mcbride D, Nakonechna A, Ortiz De Frutos J, Oude Elberink J, Proctor C, Sussman G, Sweeney C, Tian H, Weller K, Marsland A. Assessing health-utility values for chronic spontaneous/idiopathic urticaria in real-world using the EQ-5D: results from ASSURE-CSU study. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A570-1.

Martin SA, Chen K, Harris NI, Vera-Llonch M. Development of a patient-reported outcome measure for chronic hypoparathyroidism. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A679.

Mcbride D, Abuzakouk M, Balp M, Berard F, Canonica GW, Gimenez-Arnau A, Grattan C, Hollis K, Khalil S, Knulst A, Lacour J, Lynde C, Marsland A, Nakonechna A, Ortiz De Frutoz FJ, Oude Elberink J, Proctor C, Sussman G, Weller K, Maurer M. Comparative analysis of indirect costs associated with chronic spontaneous/idiopathicurticaria-results from the ASSURE-CSU study in 7 countries. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A573.

Njue A, Domdey A, Zimovetz E, Lyall M, Heyes AE, Valovirta E. The burden of comorbid allergic rhinitis and asthma. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A548.

Mytelka DS, Lorenzo M, Stafkey-Mailey D, D’yachkova Y, Nagar S, Candrilli SD, Kaye JA. Advanced soft tissue sarcoma: systemic treatment patterns and survival in Germany. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A760.

Mytelka DS, Lorenzo M, Stafkey-Mailey D, D’yachkova Y, Nagar S, Candrilli SD, Kaye JA. Real-world treatment patterns and outcomes for patients with advanced soft tissue sarcoma receiving systemic therapy in the United Kingdom. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A751.

Halliday A, Hacking V, Jugl SM, Gunda P, Nikoglou E, Miles L, Graham CN. Budget impact of secukinumab for ankylosing spondylitis in the UK. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A535.

Purser M, Mladsi DM, Kaye JA. Cost-effectiveness of sonidegib versus vismodegib for the treatment of patients with locally advanced basal cell carcinoma not amenable to surgery or radiotherapy. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A731.

Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Cost analysis of Raltegravir versus Atazanavir/r or Darunavir/r for treatment-naive adults with HIV-1 infection in Spain. Poster presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A410.

Bertwistle D, D'yachkova Y, Vickers AD, Hawe E, Fernandez M, Drove N, Lorenzo M, Wolowacz S. Comparative efficacy and saftey of interventions in the treatment of advanced soft tissue sarcoma: a systematic review and network meta analysis. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A712.

Cranmer H, Ronquest NA, Barnes A, Nadipelli VR, Akehurst R. To what extent does the published economic analyses of treatments for opioid use disorder capture its chronic, relapsing nature and its impact on society? Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A373.

Cranmer H, Ronquest NA, Barnes A, Nadipelli VR, Akehurst R. Health-related quality of life in opioid use disorder measured by utilities: a systematic literature review. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A387.

Wolowacz S, ISPOR Task Force. Response to editorial: estimating health-state utility for economic models in clinical studies: An ISPOR good research practices task force report. Value Health. 2016 Sep;19(6):702-3. doi: 10.1016/j.jval.2016.08.728

Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, Lloyd A, Norman R. Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value Health. 2016 Sep;19(2016):704-19. doi: 10.1016/j.jval.2016.06.001

Karimi P, Brazier J, Basarir H. The capability approach: a critical review of its application in health economics. Decision-Maker Commentary. Value Health. 2016 Sep;19(6):795-9. doi: 10.1016/j.jval.2016.05.006

Montejano LB, Ronquest NA, Willson TM, Wollschlaeger BA, Cole AL, Nadipelli VR. How to measure 'opioid relapse' in real-world claims data. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A72.

Poulos C. A review of discrete choice experiment studies of preferences for vaccine features. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A220.

Houghton K, Boye M, Bowman L, Brown J, Stull D. Longitudinal modeling of informatively censored patient-reported outcomes data in oncology: application to a phase III clinical trial of non-small cell lung cancer. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A158-9.

Ajmera MR, Davis KL, Price G, Li L, Huang YJ, Price GL, Goyal RK, John WJ, Cuyun Carter G, Kaye JA, Boye ME. Economic outcomes associated with tumor histology among elderly patients with metastatic non–small cell lung cancer. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A165.

Graham CN, Gunda P, Miles L, Jugl S, Palaka E, Mcbride D. A new cost-effectiveness framework for modeling psoriatic arthritis treatments. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A233-4.

Graham CN, Gunda P, Miles L, Jugl S, Palaka E, Mcbride D. A new cost-effectiveness framework for modeling ankylosing spondylitis treatments. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A234.

Tkacz JMS, Brady B, Nadipelli VR, Volpicelli J, Ronquest NA. The association between buprenorphine medication assisted treatment adherence and healthcare service utilization and costs. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A187.

Barrett AM, DiBenedetti D, Phatak H, Masseria C, Kamble S. Focus groups exploring experiences with and preferences for oral anticoagulants in people with nonvalvular atrial fibrillation. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A51.